Anika Therapeutics (ANIK) Gains from Investment Securities (2011 - 2026)
Anika Therapeutics (ANIK) reported Gains from Investment Securities of $1.7 million for Q1 2026, up 12.95% year-over-year from $1.5 million in Q1 2025, and up 29.96% quarter-over-quarter from $1.3 million in Q4 2025.
Anika Therapeutics (ANIK) Gains from Investment Securities (2011 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has 16 years of Gains from Investment Securities data on file, last reported at $1.7 million in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $1.7 million, up 12.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.9 million (up 12.3% YoY), and the FY2025 annual result was $1.8 million, down 15.51% from the prior year.
- Gains from Investment Securities climbed to $1.7 million in Q1 2026 per ANIK's latest filing, from $1.3 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $2.3 million in Q1 2024 and troughed at -$284000.0 in Q4 2022.
- A 5-year average of $500393.8 and a median of $16150.0 in 2023 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities sank 550.79% in 2022, then jumped 21100.0% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at -$284000.0 in 2022, then soared by 97.54% to -$7000.0 in 2023, then jumped by 21100.0% to $1.5 million in 2024, then dropped by 13.27% to $1.3 million in 2025, then gained by 29.96% to $1.7 million in 2026.
- Business Quant data shows ANIK's Gains from Investment Securities at $1.7 million in Q1 2026, $1.3 million in Q4 2025, and $2000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | Anika Therapeutics | 200.80 Mn | 134.01 Mn | 19.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.66 Mn |
| Mar 31, 2026 | 1.66 Mn |
| Dec 31, 2025 | 1.28 Mn |
| Dec 31, 2025 | 1.28 Mn |
| Sep 30, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 16,300.00 |
| Jun 30, 2025 | 16,300.00 |
| Mar 31, 2025 | 1.47 Mn |
| Mar 31, 2025 | 1.47 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Sep 30, 2024 | -3,000.00 |
| Sep 30, 2024 | -3,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | 2.30 Mn |
| Mar 31, 2024 | 2.30 Mn |
| Dec 31, 2023 | -7,000.00 |
| Dec 31, 2023 | -7,000.00 |